APA (7th ed.) Citation

Di Perri, D., Hartgerink, D., Terhaag, K., Houben, R., Compter, I., & Eekers, D. (2023). MO-0556 Reduction of the CTV margin in glioblastoma leads to dosimetric benefit without compromising outcome. Radiotherapy & Oncology, 182, S435. https://doi.org/10.1016/S0167-8140(23)08412-8

Chicago Style (17th ed.) Citation

Di Perri, D., D. Hartgerink, K. Terhaag, R. Houben, I. Compter, and D. Eekers. "MO-0556 Reduction of the CTV Margin in Glioblastoma Leads to Dosimetric Benefit Without Compromising Outcome." Radiotherapy & Oncology 182 (2023): S435. https://doi.org/10.1016/S0167-8140(23)08412-8.

MLA (9th ed.) Citation

Di Perri, D., et al. "MO-0556 Reduction of the CTV Margin in Glioblastoma Leads to Dosimetric Benefit Without Compromising Outcome." Radiotherapy & Oncology, vol. 182, 2023, p. S435, https://doi.org/10.1016/S0167-8140(23)08412-8.